LON:DXRX Diaceutics (DXRX) Share Price, News & Analysis → AI finds its first serious application (From Wall Street Star) (Ad) Free DXRX Stock Alerts GBX 103 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range 102▼ 10350-Day Range 93.50▼ 10752-Week Range 79▼ 110Volume5,041 shsAverage Volume59,326 shsMarket Capitalization£87.22 millionP/E Ratio10,500.00Dividend YieldN/APrice TargetGBX 150 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsInsider Trades Get Diaceutics alerts: Email Address Diaceutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside45.6% UpsideGBX 150 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares£76.50 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.49 out of 5 stars 3.5 Analyst's Opinion Consensus RatingDiaceutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDiaceutics has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for DXRX. Previous Next 0.0 Dividend Strength Dividend YieldDiaceutics does not currently pay a dividend.Dividend GrowthDiaceutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DXRX. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Diaceutics this week, compared to 0 articles on an average week. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Diaceutics insiders have sold 2,202.14% more of their company's stock than they have bought. Specifically, they have bought £33,229.88 in company stock and sold £765,000 in company stock.Percentage Held by Insiders36.31% of the stock of Diaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions51.08% of the stock of Diaceutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Diaceutics is 10,500.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 145.36.Price to Earnings Ratio vs. SectorThe P/E ratio of Diaceutics is 10,500.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 256.69.Price to Book Value per Share RatioDiaceutics has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad TranzactWhat is Medicare Supplement Insurance?Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. Learn More Here About Diaceutics Stock (LON:DXRX)Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX lab education, a suite of tailored and targeted training sessions designed to provide essential education for labs to enable and drive quality testing and biomarker knowledge; DXRX advisory boards that create and enable a valuable interface for pharmaceutical companies with a view to exploring and revealing new insights pertinent to the commercialisation and development of a therapy or companion diagnostic; and DXRX Lab Alerts, an advanced laboratory targeting service delivering tailored, short-form, quick read, educational messages with call-to-action to labs in the DXRX network. In addition, it offers implementation and consulting services for precision medicine diagnostics. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.Read More DXRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DXRX Stock News HeadlinesApril 3, 2024 | insidertrades.comPeter Keeling Sells 750,000 Shares of Diaceutics PLC (LON:DXRX) StockApril 24, 2024 | americanbankingnews.comDiaceutics (LON:DXRX) Stock Price Down 0.5%April 25, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.October 26, 2023 | finance.yahoo.comDiaceutics (LON:DXRX) shareholders have endured a 41% loss from investing in the stock three years agoOctober 26, 2023 | finance.yahoo.comDiaceutics First Half 2023 Earnings: EPS Beats ExpectationsOctober 26, 2023 | finance.yahoo.comCalculating The Intrinsic Value Of Diaceutics PLC (LON:DXRX)April 20, 2023 | finance.yahoo.comDiaceutics PLC (LON:DXRX) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies AheadApril 20, 2023 | finance.yahoo.comDiaceutics PLC (LON:DXRX) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?April 25, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.April 17, 2023 | marketwatch.comDiaceutics 2022 Pretax Profit Rose on Growing DemandMarch 13, 2023 | marketwatch.comDiaceutics Suspends Share Trading as SVB Closure Restricts Access to Its FundsMarch 10, 2023 | finance.yahoo.comThose who invested in Diaceutics (LON:DXRX) a year ago are up 13%January 28, 2023 | finance.yahoo.comBroker Revenue Forecasts For Diaceutics PLC (LON:DXRX) Are Surging HigherJanuary 27, 2023 | lse.co.ukTRADING UPDATES: Diaceutics wins two deals; Faron proposes placingDecember 9, 2022 | finance.yahoo.comAn Intrinsic Calculation For Diaceutics PLC (LON:DXRX) Suggests It's 40% UndervaluedNovember 28, 2022 | msn.comDanske Bank supported the purchase of the new building at Kings Hall Life Sciences ParkSeptember 29, 2022 | finance.yahoo.comEdited Transcript of DXRX.L earnings conference call or presentation 28-Sep-22 12:00pm GMTSeptember 16, 2022 | nz.finance.yahoo.comDEWA and WGEO Complete Preparations for 8th Edition of the World Green Economy SummitSeptember 16, 2022 | yahoo.comBake Off star Laura Adlington reveals she was left suicidal after trolls fat-shamed her on social mediaAugust 14, 2022 | uk.finance.yahoo.comDiaceutics PLC (DXRX.L)July 2, 2022 | finance.yahoo.comIs Diaceutics PLC (LON:DXRX) Trading At A 32% Discount?June 13, 2022 | lse.co.ukDiaceutics wins USD2 million contract with "top five global" drug firmMay 23, 2022 | finance.yahoo.comDiaceutics PLC (LON:DXRX) Has Varied Financials: Could That Be Why Its Recent Performance Has Been Uneventful?May 5, 2022 | lse.co.ukDiaceutics inks five-year deal with existing pharma partnerApril 7, 2022 | finance.yahoo.comThe past year for Diaceutics (LON:DXRX) investors has not been profitableMarch 22, 2022 | lse.co.ukDiaceutics returns to pretax profit in 2021 and ups revenueMarch 16, 2022 | marketwatch.comDiaceutics Approved by US Agency to Receive Enhanced DataSee More Headlines Receive DXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Diaceutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolLON:DXRX CUSIPN/A CIKN/A Webwww.diaceutics.com PhoneN/AFaxN/AEmployees151Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 150 High Stock Price TargetGBX 150 Low Stock Price TargetGBX 150 Potential Upside/Downside+45.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio10,500.00 Forward P/E Ratio33.12 P/E GrowthN/ANet IncomeN/A Net Margins0.03% Pretax MarginN/A Return on Equity0.01% Return on Assets-0.72% Debt Debt-to-Equity Ratio3.07 Current Ratio7.99 Quick Ratio9.92 Sales & Book Value Annual Sales£21.90 million Price / Sales3.98 Cash FlowGBX 33.01 per share Price / Cash Flow3.12 Book ValueGBX 49 per share Price / Book2.10Miscellaneous Outstanding Shares84,680,000Free FloatN/AMarket Cap£87.22 million OptionableNot Optionable Beta0.42 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Ryan Keeling (Age 42)CEO & Director Comp: $334.27kMr. Peter Keeling (Age 64)Founder & Executive Director Comp: $363.24kMr. Nicholas Stewart Roberts (Age 42)CFO & Director Comp: $180.37kMs. Julie BrowneChief Operating OfficerMs. Gillian ShawGeneral CounselMs. Norma ThompsonGlobal Head of Human ResourcesMr. Jordan ClarkChief Commercial OfficerMs. Susanne MunkstedChief Precision Medicine OfficerMs. Jillian BeggsChief Commercial OfficerMs. Marieke HoefsmitSenior Director & Head of Data Delivery NetherlandsMore ExecutivesKey CompetitorsANGLELON:AGLFaron Pharmaceuticals OyLON:FARNScancellLON:SCLPSourcebio InternationalLON:SBIMereo BioPharma Group plc (MPH.L)LON:MPHView All CompetitorsInsidersPeter KeelingSold 750,000 sharesTotal: £76.50 M ($102.00/share)Graham PatersonBought 33,564 shares on 3/6/2024Total: £3.32 M ($99.00/share)Nick RobertsBought 152 shares on 1/30/2024Total: £152.00 ($1.00/share)Nick RobertsBought 170 shares on 10/27/2023Total: £14,960.00 ($88.00/share)Nick RobertsBought 139 shares on 8/29/2023Total: £139.00 ($1.00/share)View All Insider Transactions DXRX Stock Analysis - Frequently Asked Questions Should I buy or sell Diaceutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Diaceutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DXRX shares. View DXRX analyst ratings or view top-rated stocks. What is Diaceutics' stock price target for 2024? 2 brokers have issued 1-year target prices for Diaceutics' shares. Their DXRX share price targets range from GBX 150 to GBX 150. On average, they expect the company's share price to reach GBX 150 in the next year. This suggests a possible upside of 45.6% from the stock's current price. View analysts price targets for DXRX or view top-rated stocks among Wall Street analysts. How have DXRX shares performed in 2024? Diaceutics' stock was trading at GBX 87 at the beginning of 2024. Since then, DXRX stock has increased by 18.4% and is now trading at GBX 103. View the best growth stocks for 2024 here. How do I buy shares of Diaceutics? Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:DXRX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Diaceutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
